1. Academic Validation
  2. Potent PPARα activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice

Potent PPARα activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice

  • PLoS One. 2012;7(2):e31317. doi: 10.1371/journal.pone.0031317.
Young-il Kim 1 Shizuka Hirai Tsuyoshi Goto Chie Ohyane Haruya Takahashi Taneaki Tsugane Chiaki Konishi Takashi Fujii Shuji Inai Yoko Iijima Koh Aoki Daisuke Shibata Nobuyuki Takahashi Teruo Kawada
Affiliations

Affiliation

  • 1 Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan.
Abstract

Dyslipidemia is a major risk factor for development of several obesity-related diseases. The Peroxisome Proliferator-activated Receptor α (PPARα) is a ligand-activated transcription factor that regulates energy metabolism. Previously, we reported that 9-oxo-10,12-octadecadienoic acid (9-oxo-ODA) is presented in fresh tomato fruits and acts as a PPARα Agonist. In addition to 9-oxo-ODA, we developed that 13-oxo-9,11-octadecadienoic acid (13-oxo-ODA), which is an isomer of 9-oxo-ODA, is present only in tomato juice. In this study, we explored the possibility that 13-oxo-ODA acts as a PPARα Agonist in vitro and whether its effect ameliorates dyslipidemia and hepatic steatosis in vivo. In vitro luciferase assay experiments revealed that 13-oxo-ODA significantly induced PPARα activation; moreover, the luciferase activity of 13-oxo-ODA was stronger than that of 9-oxo-ODA and conjugated linoleic acid (CLA), which is a precursor of 13-oxo-ODA and is well-known as a potent PPARα Activator. In addition to in vitro experiment, treatment with 13-oxo-ODA decreased the levels of plasma and hepatic triglycerides in obese KK-Ay mice fed a high-fat diet. In conclusion, our findings indicate that 13-oxo-ODA act as a potent PPARα Agonist, suggesting a possibility to improve obesity-induced dyslipidemia and hepatic steatosis.

Figures
Products